세계의 의약품 수탁 제조 시장(-2030년) : 서비스별, 생물제제별, 분자별

The global pharmaceutical contract manufacturing market is projected to reach USD 311.95 billion by 2030 from an estimated USD 209.90 billion in 2025, at a CAGR of 8.2% from 2025 to 2030.

The expansion of the pharmaceutical contract manufacturing market has been predominantly fueled by outsourcing for GLP-1 manufacturing & development, ADC approvals and programs, and loss of exclusivity for blockbuster biologics. However, expansion of in-house capacities by pharmaceutical companies and pricing pressure in the US and Europe are expected to restrict market growth.

The biologics FDF manufacturing services segment reported the highest CAGR in 2024.

Based on biologics manufacturing service, the pharmaceutical contract manufacturing market is segmented into biologics API manufacturing services and biologics FDF Manufacturing Services. Among these, biologics FDF manufacturing services are projected to experience the fastest growth rate during the forecast period from 2025 to 2030. This strong growth outlook is primarily driven by the surging demand for biologics, which include complex and high-value products such as monoclonal antibodies, recombinant proteins, cell and gene therapies, and vaccines. The rising focus on targeted pharmacological therapies, which offer greater efficacy and reduced side effects compared to traditional treatments, is further boosting demand for specialized manufacturing capabilities. In addition, the increasing volume of research and development activities, particularly in cell and gene therapy, contributes significantly to market expansion. A growing number of pipeline candidates in these advanced therapeutic areas requires highly specialized manufacturing processes, encouraging pharmaceutical companies to partner with CDMOs possessing the necessary expertise, infrastructure, and regulatory compliance. This trend is expected to result in higher investment in advanced biologics production technologies, capacity expansion, and quality systems within CDMOs. Consequently, the FDF manufacturing services segment is well-positioned to achieve substantial growth and play an increasingly critical role in the pharmaceutical outsourcing landscape over the coming years.

The small molecules segment dominated the pharmaceutical contract manufacturing market in 2024.

The pharmaceutical contract manufacturing market is segmented by molecules into small molecules & large molecules. In 2024, small molecules, encompassing high-potency small molecules, oligonucleotides and synthetic peptides, radiopharmaceuticals, and other small molecules, hold the largest share of the pharmaceutical CDMO market by molecule segment. High-potency small molecules, particularly oncology, require specialized containment and expertise, driving demand for CDMOs with advanced facilities. Oligonucleotides and synthetic peptides have gained momentum due to their role in precision medicine and targeted therapies, offering new outsourcing opportunities. Radiopharmaceuticals, with applications in diagnostics and treatment, are seeing increased interest as nuclear medicine expands. The other small molecules category remains vital for numerous therapeutic areas, from cardiovascular to infectious diseases. Small molecules are favored for their stability, oral bioavailability, and cost-efficient mass production, making them attractive for both innovative and generic drug pipelines. The growing prevalence of chronic conditions, coupled with ongoing innovation in synthetic chemistry and continuous manufacturing, strengthens their market position. CDMOs with specialized expertise across these subcategories can leverage strong demand from pharmaceutical companies seeking speed, flexibility, and cost efficiency, ensuring that small molecules continue to be a core driver of the CDMO industry's growth.

North America accounted for the largest share in the global pharmaceutical contract manufacturing market from 2025 to 2030.

North America dominated the pharmaceutical CDMO market in 2024, driven by its strong regulatory framework, advanced manufacturing infrastructure, and high concentration of leading CDMO players. The region benefits from a well-established pharmaceutical industry, extensive R&D capabilities, and a strong presence of big pharmaceutical companies outsourcing development and manufacturing to optimize costs and speed to market. Supportive regulatory agencies, particularly the US FDA, promote innovation through clear guidelines and expedited approvals, encouraging investment in advanced manufacturing technologies such as continuous processing and high-potency API production. North America also leads in biologics and advanced therapies manufacturing, supported by specialized CDMO facilities catering to cell and gene therapies. Strategic collaborations, mergers, and acquisitions further enhance service portfolios and capacity. The region's robust venture capital ecosystem and academic-industry partnerships foster innovation, while its focus on quality, compliance, and scalability attracts global clients.

The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side- 30%
• By Designation: Managers- 45%, CXO and Directors- 30%, and Executives- 25%
• By Region: North America- 30%, Europe- 30%, Asia Pacific- 30%, Latin America- 5%, and the Middle East & Africa- 5%

Key Companies

Key players in the pharmaceutical contract manufacturing market include Thermo Fisher Scientific Inc. (US), Lonza (Switzerland), WuXi AppTec (China), WuXi Biologics (China), AbbVie Inc. (US), Catalent, Inc. (Novo Holdings) (US), Samsung Biologics (South Korea), Evonik (Germany), FUJIFILM Holding Corporation (Japan), Siegfried Holding AG (Switzerland), and Boehringer Ingelheim International GmbH (Germany). Other notable companies are Merck KGaA (Germany), Almac Group (UK), Charles River Laboratories (US), Asymchem Inc. (China), Vetter (Germany), and Alcami Corporation (US).

Research Coverage

This research report categorizes the pharmaceutical contract manufacturing market, by service {drug development services, pharmaceutical manufacturing services [pharmaceutical API manufacturing services, pharmaceutical FDF manufacturing services (parenteral, tablet, capsule, oral liquid, semi-solid, other formulations), biologics manufacturing services (biologics API manufacturing services, biologics FDF manufacturing services)], packaging & labelling services, fill-finish services, other services}, molecule [small molecules (high-potency small molecules, oligonucleotide & synthetic peptides, radiopharmaceutical, and other molecules) large molecules (mAbs, CGT, ADC, vaccines, therapeutic peptides & proteins, and other large molecules)], end user (big pharmaceutical companies, small & mid-sized pharmaceutical companies, generic pharmaceutical companies, other end users), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the pharmaceutical contract manufacturing market. A detailed analysis of the key industry players has been done to provide insights into their business overview, solutions, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, acquisitions, and recent developments associated with the pharmaceutical contract manufacturing market.

Reasons to buy this report

The report will help market leaders and new entrants by providing them with closest approximations of the revenue numbers for the overall pharmaceutical contract manufacturing market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better positioning their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (GLP-1 capacity crunch, increasing development and manufacturing of antibody drug conjugates, loss of exclusivity of blockbuster biologics, increasing complexity of injectable drug formats) restraints (pricing pressure on innovator drugs, growing penetration of generics and biosimilars, strict regulatory compliance, risk in advanced therapies pipeline), opportunities (Rising demand for cell and gene therapies, growing inclination toward one-stop-shop model, market expansion in emerging countries, booming radiopharmaceutical and nuclear medicine segment), and challenges (global trade instability and insourcing) influencing the growth of pharmaceutical contract development and manufacturing market.
• Service Development/Innovation: Thorough investigation of recently launched services available in the pharmaceutical contract manufacturing market.
• Market Development: Utilizing analysis of regional market trends, the study offers comprehensive knowledge on profitable markets.
• Market Diversification: Comprehensive information on new services, underdeveloped areas, present developments, and pharmaceutical contract manufacturing sector investments is what market diversification is based on.
• Competitive Assessment: A comprehensive evaluation of the market shares, growth strategies, and service offerings of prominent companies such as Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza (Switzerland), AbbVie Inc. (US), WuXi AppTec (China), and others in the pharmaceutical contract development and manufacturing market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key objectives of secondary research
    • 2.1.1.2 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET SIZE ESTIMATION
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Company revenue analysis (Bottom-up approach)
    • 2.2.1.2 MnM repository analysis
    • 2.2.1.3 Primary interviews
  • 2.2.2 INSIGHTS FROM PRIMARY EXPERTS
  • 2.2.3 SEGMENTAL MARKET SIZE ESTIMATION (TOP-DOWN APPROACH)
• 2.3 GROWTH RATE PROJECTIONS
• 2.4 DATA TRIANGULATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

• 3.1 STRATEGIC IMPERATIVES FOR KEY STAKEHOLDERS
  • 3.1.1 PHARMACEUTICAL CONTRACT MANUFACTURERS
    • 3.1.1.1 Capacity lock in for GLP-1 and biologics opportunities
    • 3.1.1.2 Sterile fill-finish services
    • 3.1.1.3 OSD differentiation and dual site sourcing
  • 3.1.2 PHARMACEUTICAL COMPANIES
    • 3.1.2.1 Own vs. outsourcing critical steps
    • 3.1.2.2 Dual-source, multi-site supply resilience
  • 3.1.3 STARTUPS AND INNOVATIVE BIOTECH FIRMS
    • 3.1.3.1 Gene-to-IND platform
    • 3.1.3.2 Clinical supply risk management

4 PREMIUM INSIGHTS

• 4.1 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET OVERVIEW
• 4.2 NORTH AMERICA: PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE AND COUNTRY, 2025
• 4.3 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE
• 4.4 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER
• 4.5 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
• 4.6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 GLP-1 capacity crunch
    • 5.2.1.2 Increasing development and manufacturing of antibody drug conjugates
    • 5.2.1.3 Loss of exclusivity of blockbuster biologics
    • 5.2.1.4 Increasing complexity of injectable drug formats
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Pricing pressure on innovator drugs
    • 5.2.2.2 Growing penetration of generics and biosimilars
    • 5.2.2.3 Strict regulatory compliance
    • 5.2.2.4 Risk in advanced therapies pipeline
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Rising demand for cell and gene therapies
    • 5.2.3.2 Growing inclination toward one-stop-shop model
    • 5.2.3.3 Market expansion in emerging countries
    • 5.2.3.4 Booming radiopharmaceutical and nuclear medicine segment
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Global trade instability and insourcing
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.4 PRICING ANALYSIS
  • 5.4.1 INDICATIVE PRICING ANALYSIS, BY SERVICE
  • 5.4.2 INDICATIVE PRICING ANALYSIS, BY REGION
  • 5.4.3 COMPARISON OF CDMO PRICING MODELS
• 5.5 VALUE CHAIN ANALYSIS
• 5.6 SUPPLY CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 MANUFACTURING SITE, EXPANSION, AND CAPEX TREND OF KEY CDMOS
• 5.8 INVESTMENT AND FUNDING SCENARIO
• 5.9 TECHNOLOGY ANALYSIS
  • 5.9.1 KEY TECHNOLOGIES
    • 5.9.1.1 Single-use bioprocessing systems
    • 5.9.1.2 Continuous manufacturing
    • 5.9.1.3 Advanced formulation technologies
  • 5.9.2 COMPLEMENTARY TECHNOLOGIES
    • 5.9.2.1 High-performance liquid chromatography
    • 5.9.2.2 Mass spectrometry
    • 5.9.2.3 Next-generation sequencing
    • 5.9.2.4 Automation and robotics
    • 5.9.2.5 Process analytical technology
  • 5.9.3 ADJACENT TECHNOLOGIES
    • 5.9.3.1 3D printing
    • 5.9.3.2 Artificial intelligence and machine learning
• 5.10 PATENT ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS, 2025-2026
• 5.12 REGULATORY LANDSCAPE
  • 5.12.1 REGULATORY SCENARIO
  • 5.12.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 BARGAINING POWER OF SUPPLIERS
  • 5.13.2 BARGAINING POWER OF BUYERS
  • 5.13.3 THREAT OF NEW ENTRANTS
  • 5.13.4 THREAT OF SUBSTITUTES
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 BUYING CRITERIA
• 5.15 UNMET NEEDS OF END USERS
  • 5.15.1 CAPACITY AND TIMELY ACCESS
  • 5.15.2 COST EFFICIENCY AND FLEXIBILITY
  • 5.15.3 END-TO-END INTEGRATED SERVICES
  • 5.15.4 ADVANCED MODALITY EXPERTISE
  • 5.15.5 QUALITY AND REGULATORY CONSISTENCY
• 5.16 ABBREVIATED NEW DRUG APPLICATION (ANDA) APPROVALS
• 5.17 IMPACT OF AI/GEN AI ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL OF AI/GEN AI
  • 5.17.3 AI USE CASES
  • 5.17.4 KEY COMPANIES IMPLEMENTING AI/GEN AI
• 5.18 IMPACT OF 2025 US TARIFFS ON PHARMACEUTICAL CONTRACT MANUFACTURING MARKET
  • 5.18.1 INTRODUCTION
  • 5.18.2 KEY TARIFF RATES
  • 5.18.3 PRICE IMPACT ANALYSIS
  • 5.18.4 IMPACT ON COUNTRY/REGION
    • 5.18.4.1 US
    • 5.18.4.2 Europe
    • 5.18.4.3 Asia Pacific
      • 5.18.4.3.1 India
  • 5.18.5 IMPACT ON END-USE INDUSTRIES

6 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY SERVICE

• 6.1 INTRODUCTION
• 6.2 PHARMACEUTICAL MANUFACTURING SERVICES
  • 6.2.1 PHARMACEUTICAL API MANUFACTURING SERVICES
    • 6.2.1.1 Rising cases of patent expiry to fuel market
  • 6.2.2 PHARMACEUTICAL FDF MANUFACTURING SERVICES
    • 6.2.2.1 Parenteral manufacturing services
      • 6.2.2.1.1 Increasing demand for specialized manufacturing capabilities to support growth
    • 6.2.2.2 Tablet manufacturing services
      • 6.2.2.2.1 Growing domestic production capacity in emerging markets to boost market
    • 6.2.2.3 Capsule manufacturing services
      • 6.2.2.3.1 Rising adoption in pharmaceutical, nutraceutical, and cosmetic applications to stimulate growth
    • 6.2.2.4 Oral liquid manufacturing services
      • 6.2.2.4.1 Growing preference for oral liquids over powders to fuel market
    • 6.2.2.5 Semi-solid manufacturing services
      • 6.2.2.5.1 Rising prevalence of skin infections and burns to foster growth
    • 6.2.2.6 Other FDF manufacturing services
• 6.3 DRUG DEVELOPMENT SERVICES
  • 6.3.1 INCREASING COST OF DRUG DISCOVERY AND DEVELOPMENT TO EXPEDITE GROWTH
• 6.4 BIOLOGICS MANUFACTURING SERVICES
  • 6.4.1 BIOLOGICS API MANUFACTURING SERVICES
    • 6.4.1.1 Rising investments in single-use production capacities to bolster growth
  • 6.4.2 BIOLOGICS FDF MANUFACTURING SERVICES
    • 6.4.2.1 Growing demand for generic medicines and biologics to fuel market
• 6.5 PACKAGING & LABELING SERVICES
  • 6.5.1 INCREASING COMPLEXITY AND STRINGENCY OF REGULATORY REQUIREMENTS FOR DRUG SAFETY AND EFFICACY TO FAVOR GROWTH
• 6.6 FILL-FINISH SERVICES
  • 6.6.1 SURGE IN DEMAND FOR BIOLOGICS AND COMPLEX INJECTABLE THERAPIES TO BOOST MARKET
• 6.7 OTHER SERVICES

7 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY MOLECULE

• 7.1 INTRODUCTION
• 7.2 SMALL MOLECULES
  • 7.2.1 HIGH-POTENCY SMALL MOLECULES
    • 7.2.1.1 Increasing adoption of high-potency small molecules for treating oncology, rare diseases, and other diseases to aid growth
  • 7.2.2 OLIGONUCLEOTIDE & SYNTHETIC PEPTIDES
    • 7.2.2.1 Growing focus on next-gen therapies to drive market
  • 7.2.3 RADIOPHARMACEUTICAL MOLECULES
    • 7.2.3.1 Advances in isotope production, radiolabeling chemistry, and theranostic approaches to boost market
  • 7.2.4 OTHER SMALL MOLECULES
• 7.3 LARGE MOLECULES
  • 7.3.1 MONOCLONAL ANTIBODIES
    • 7.3.1.1 Rising use of mAbs in managing cancer, autoimmune disorders, and osteoporosis to spur growth
  • 7.3.2 CELL & GENE THERAPIES
    • 7.3.2.1 Emerging treatments for previously untreatable genetic and rare diseases to boost market
  • 7.3.3 ANTIBODY DRUG CONJUGATES
    • 7.3.3.1 Growing need for precision medicines to fuel market
  • 7.3.4 VACCINES
    • 7.3.4.1 Growing threat of infectious disease outbreaks to drive market
  • 7.3.5 THERAPEUTIC PEPTIDES & PROTEINS
    • 7.3.5.1 Increasing research in genomics to support growth
  • 7.3.6 OTHER LARGE MOLECULES

8 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY END USER

• 8.1 INTRODUCTION
• 8.2 BIG PHARMACEUTICAL COMPANIES
  • 8.2.1 PRICING PRESSURE IN PHARMACEUTICAL INDUSTRY TO CONTRIBUTE TO GROWTH
• 8.3 SMALL & MEDIUM-SIZED PHARMACEUTICAL COMPANIES
  • 8.3.1 NEED TO SAVE IN-HOUSE DRUG MANUFACTURING COST TO FOSTER GROWTH
• 8.4 GENERIC PHARMACEUTICAL COMPANIES
  • 8.4.1 FAVORABLE GOVERNMENT SUPPORT FOR ADOPTION OF GENERIC DRUGS TO PROPEL MARKET
• 8.5 OTHER END USERS

9 PHARMACEUTICAL CONTRACT MANUFACTURING MARKET, BY REGION

• 9.1 INTRODUCTION
• 9.2 NORTH AMERICA
  • 9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 9.2.2 US
    • 9.2.2.1 High clinical trial and drug discovery activities to foster growth
  • 9.2.3 CANADA
    • 9.2.3.1 Favorable government support and increased focus on R&D activities to sustain growth
• 9.3 EUROPE
  • 9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 9.3.2 GERMANY
    • 9.3.2.1 Free drug-pricing policy and high pharmaceutical investments to speed up growth
  • 9.3.3 UK
    • 9.3.3.1 Favorable R&D funding scenario to augment growth
  • 9.3.4 FRANCE
    • 9.3.4.1 Booming life science research and growing generics market to drive market
  • 9.3.5 ITALY
    • 9.3.5.1 Rising commercial drug development and increasing life science R&D to favor growth
  • 9.3.6 SWITZERLAND
    • 9.3.6.1 Rapid growth as global pharmaceutical manufacturing hub to drive market
  • 9.3.7 POLAND
    • 9.3.7.1 Universal health coverage and advanced government-supported medical infrastructure to encourage growth
  • 9.3.8 SPAIN
    • 9.3.8.1 Growing pharmaceutical R&D expenditure and increasing outsourcing of trial phases to boost market
  • 9.3.9 REST OF EUROPE
• 9.4 ASIA PACIFIC
  • 9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 9.4.2 CHINA
    • 9.4.2.1 Made in China 2025 initiative and high government drug development investments to aid growth
  • 9.4.3 JAPAN
    • 9.4.3.1 High geriatric population and advanced pharmaceutical research to augment growth
  • 9.4.4 SOUTH KOREA
    • 9.4.4.1 Increased biotech investments and developed pharma sector to propel market
  • 9.4.5 INDIA
    • 9.4.5.1 Favorable industrial environment and lower labor costs to drive market
  • 9.4.6 AUSTRALIA
    • 9.4.6.1 Strategic geographical location and stringent regulatory environment to foster growth
  • 9.4.7 REST OF ASIA PACIFIC
• 9.5 LATIN AMERICA
  • 9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 9.5.2 BRAZIL
    • 9.5.2.1 Rapid patient enrolment and increased focus on advanced clinical trials to expedite growth
  • 9.5.3 MEXICO
    • 9.5.3.1 Surge in pharmaceutical goods export to promote growth
  • 9.5.4 REST OF LATIN AMERICA
• 9.6 MIDDLE EAST
  • 9.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 9.6.2 GCC COUNTRIES
    • 9.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 9.6.2.1.1 Increasing healthcare expenditure to aid growth
    • 9.6.2.2 UAE
      • 9.6.2.2.1 Strategic government healthcare initiatives and broader economic diversification plans to drive market
    • 9.6.2.3 Rest of GCC countries
  • 9.6.3 REST OF MIDDLE EAST
• 9.7 AFRICA
  • 9.7.1 RISING PREVALENCE OF CHRONIC DISEASES TO FACILITATE GROWTH
  • 9.7.2 MACROECONOMIC OUTLOOK OF AFRICA

10 COMPETITIVE LANDSCAPE

• 10.1 INTRODUCTION
• 10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
• 10.3 REVENUE SHARE ANALYSIS, 2020-2024
• 10.4 MARKET SHARE ANALYSIS, 2024
• 10.5 COMPANY VALUATION AND FINANCIAL METRICS
• 10.6 BRAND/SERVICE COMPARISON
  • 10.6.1 THERMO FISHER SCIENTIFIC INC.
  • 10.6.2 LONZA
  • 10.6.3 WUXI BIOLOGICS AND WUXI APPTEC
  • 10.6.4 CATALENT, INC.
  • 10.6.5 SAMSUNG BIOLOGICS
• 10.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 10.7.1 STARS
  • 10.7.2 EMERGING LEADERS
  • 10.7.3 PERVASIVE PLAYERS
  • 10.7.4 PARTICIPANTS
  • 10.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 10.7.5.1 Company footprint
    • 10.7.5.2 Region footprint
    • 10.7.5.3 Service footprint
    • 10.7.5.4 Molecule footprint
• 10.8 COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024
  • 10.8.1 PROGRESSIVE COMPANIES
  • 10.8.2 RESPONSIVE COMPANIES
  • 10.8.3 DYNAMIC COMPANIES
  • 10.8.4 STARTING BLOCKS
  • 10.8.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 10.8.5.1 Detailed list of key startups/SMEs
    • 10.8.5.2 Competitive benchmarking of key startups/SMEs
• 10.9 COMPETITIVE SCENARIO
  • 10.9.1 SERVICE LAUNCHES
  • 10.9.2 DEALS
  • 10.9.3 EXPANSIONS

11 COMPANY PROFILES

• 11.1 KEY PLAYERS
  • 11.1.1 THERMO FISHER SCIENTIFIC INC.
    • 11.1.1.1 Business overview
    • 11.1.1.2 Services offered
    • 11.1.1.3 Recent developments
      • 11.1.1.3.1 Service launches
      • 11.1.1.3.2 Deals
    • 11.1.1.4 MnM view
      • 11.1.1.4.1 Key strengths
      • 11.1.1.4.2 Strategic choices
      • 11.1.1.4.3 Weaknesses and competitive threats
  • 11.1.2 LONZA
    • 11.1.2.1 Business overview
    • 11.1.2.2 Services offered
    • 11.1.2.3 Recent developments
      • 11.1.2.3.1 Deals
      • 11.1.2.3.2 Expansions
    • 11.1.2.4 MnM view
      • 11.1.2.4.1 Key strengths
      • 11.1.2.4.2 Strategic choices
      • 11.1.2.4.3 Weaknesses and competitive threats
  • 11.1.3 CATALENT, INC.
    • 11.1.3.1 Business overview
    • 11.1.3.2 Services offered
    • 11.1.3.3 Recent developments
      • 11.1.3.3.1 Service launches
      • 11.1.3.3.2 Deals
      • 11.1.3.3.3 Expansions
    • 11.1.3.4 MnM view
      • 11.1.3.4.1 Key strengths
      • 11.1.3.4.2 Strategic choices
      • 11.1.3.4.3 Weaknesses and competitive threats
  • 11.1.4 WUXI APPTEC
    • 11.1.4.1 Business overview
    • 11.1.4.2 Services offered
    • 11.1.4.3 Recent developments
      • 11.1.4.3.1 Deals
      • 11.1.4.3.2 Expansions
    • 11.1.4.4 MnM view
      • 11.1.4.4.1 Key strengths
      • 11.1.4.4.2 Strategic choices
      • 11.1.4.4.3 Weaknesses and competitive threats
  • 11.1.5 WUXI BIOLOGICS
    • 11.1.5.1 Business overview
    • 11.1.5.2 Services offered
    • 11.1.5.3 Recent developments
      • 11.1.5.3.1 Service launches
      • 11.1.5.3.2 Deals
      • 11.1.5.3.3 Expansions
      • 11.1.5.3.4 Other developments
  • 11.1.6 SAMSUNG BIOLOGICS
    • 11.1.6.1 Business overview
    • 11.1.6.2 Services offered
    • 11.1.6.3 Recent developments
      • 11.1.6.3.1 Service launches
      • 11.1.6.3.2 Deals
      • 11.1.6.3.3 Expansions
  • 11.1.7 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 11.1.7.1 Business overview
    • 11.1.7.2 Services offered
    • 11.1.7.3 Recent developments
      • 11.1.7.3.1 Deals
      • 11.1.7.3.2 Expansions
      • 11.1.7.3.3 Other developments
  • 11.1.8 EVONIK
    • 11.1.8.1 Business overview
    • 11.1.8.2 Services offered
    • 11.1.8.3 Recent developments
      • 11.1.8.3.1 Deals
      • 11.1.8.3.2 Expansions
  • 11.1.9 FUJIFILM HOLDINGS CORPORATION
    • 11.1.9.1 Business overview
    • 11.1.9.2 Services offered
    • 11.1.9.3 Recent developments
      • 11.1.9.3.1 Deals
      • 11.1.9.3.2 Expansions
  • 11.1.10 ABBVIE INC.
    • 11.1.10.1 Business overview
    • 11.1.10.2 Services offered
    • 11.1.10.3 Recent developments
      • 11.1.10.3.1 Deals
      • 11.1.10.3.2 Expansions
  • 11.1.11 SIEGFRIED HOLDING AG
    • 11.1.11.1 Business overview
    • 11.1.11.2 Services offered
    • 11.1.11.3 Recent developments
      • 11.1.11.3.1 Deals
      • 11.1.11.3.2 Expansions
  • 11.1.12 MERCK KGAA
    • 11.1.12.1 Business overview
    • 11.1.12.2 Services offered
    • 11.1.12.3 Recent developments
      • 11.1.12.3.1 Deals
      • 11.1.12.3.2 Expansions
  • 11.1.13 ALMAC GROUP
    • 11.1.13.1 Business overview
    • 11.1.13.2 Services offered
    • 11.1.13.3 Recent developments
      • 11.1.13.3.1 Deals
      • 11.1.13.3.2 Expansions
  • 11.1.14 CHARLES RIVER LABORATORIES
    • 11.1.14.1 Business overview
    • 11.1.14.2 Services offered
    • 11.1.14.3 Recent developments
      • 11.1.14.3.1 Deals
      • 11.1.14.3.2 Expansions
  • 11.1.15 ASYMCHEM INC.
    • 11.1.15.1 Business overview
    • 11.1.15.2 Services offered
    • 11.1.15.3 Recent developments
      • 11.1.15.3.1 Deals
      • 11.1.15.3.2 Expansions
  • 11.1.16 VETTER
    • 11.1.16.1 Business overview
    • 11.1.16.2 Services offered
    • 11.1.16.3 Recent developments
      • 11.1.16.3.1 Service launches
      • 11.1.16.3.2 Deals
      • 11.1.16.3.3 Expansions
  • 11.1.17 ALCAMI CORPORATION
    • 11.1.17.1 Business overview
    • 11.1.17.2 Services offered
    • 11.1.17.3 Recent developments
      • 11.1.17.3.1 Deals
      • 11.1.17.3.2 Expansions
  • 11.1.18 EUROFINS SCIENTIFIC
    • 11.1.18.1 Business overview
    • 11.1.18.2 Services offered
    • 11.1.18.3 Recent developments
      • 11.1.18.3.1 Expansions
• 11.2 OTHER PLAYERS
  • 11.2.1 PIRAMAL PHARMA SOLUTIONS
  • 11.2.2 SYNGENE INTERNATIONAL LIMITED
  • 11.2.3 CAMBREX CORPORATION
  • 11.2.4 JUBILANT PHARMANOVA LIMITED
  • 11.2.5 YUHAN CORPORATION
  • 11.2.6 PIERRE FABRE LABORATORIES
  • 11.2.7 PFIZER CENTREONE
  • 11.2.8 DELPHARM
  • 11.2.9 FRONTAGE LABS
  • 11.2.10 SHARP SERVICES, LLC
  • 11.2.11 GRAND RIVER ASEPTIC MANUFACTURING
  • 11.2.12 RECIPHARM AB
  • 11.2.13 PCI PHARMA SERVICES
  • 11.2.14 CURIA GLOBAL, INC.
  • 11.2.15 SIMTRA BIOPHARMA SOLUTIONS
  • 11.2.16 PORTON
  • 11.2.17 MABPLEX INTERNATIONAL CO. LTD.
  • 11.2.18 CELLARES

12 APPENDIX

• 12.1 DISCUSSION GUIDE
• 12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 12.3 CUSTOMIZATION OPTIONS
• 12.4 RELATED REPORTS
• 12.5 AUTHOR DETAILS